PMID- 18489995
OWN - NLM
STAT- MEDLINE
DCOM- 20080819
LR  - 20151119
IS  - 1523-6536 (Electronic)
IS  - 1083-8791 (Linking)
VI  - 14
IP  - 6
DP  - 2008 Jun
TI  - Recipient-derived cells after cord blood transplantation: dynamics elucidated by 
      multicolor FACS, reflecting graft failure and relapse.
PG  - 693-701
LID - 10.1016/j.bbmt.2008.04.001 [doi]
AB  - Although umbilical cord blood has been increasingly used as an alternative donor 
      source to treat hematologic malignancies, cord blood transplantation (CBT) is 
      frequently complicated by graft failure and relapse of primary diseases. Because 
      persistence or increase of recipient-derived hematopoietic or malignant cells has 
      pathogenic import under these conditions, analysis of recipient-derived cells 
      should be useful to understand the pathogenesis of graft failure and relapse of 
      primary disease. Because most CBT involves human leukocyte antigen 
      (HLA)-mismatched transplantation, we developed a 9-color fluorescence activated 
      cell sorter (FACS)-based method of mixed chimerism (MC) analysis using anti-HLA 
      antibodies to detect mismatched antigens (HLA-Flow method). Among CD4(+) T cells, 
      CD8(+) T cells, B cells, NK cells, monocytes, and granulocytes, donor- and 
      recipient-derived cells alike could be individually analyzed simultaneously in a 
      rapid, quantitative and highly sensitive manner, making the HLA-Flow method very 
      valuable in monitoring the engraftment process. In addition, this method was also 
      useful in monitoring recipient-derived cells with leukemia-specific phenotypes, 
      both as minimal residual disease (MRD) and as early harbingers of relapse. 
      Leukemia relapse can be definitively diagnosed by cytogenetic or PCR studies 
      using recipient-derived cells sorted for leukemia markers. Multicolor HLA-fFlow 
      analysis and cell sorting in early diagnosis of graft failure and relapse was 
      confirmed as valuable in 14 patients who had received HLA-mismatched CBT.
FAU - Watanabe, Nobukazu
AU  - Watanabe N
AD  - FACS Core Laboratory, The Institute of Medical Science, The University of Tokyo, 
      Tokyo, Japan. nwatanab@ims.u-tokyo.ac.jp
FAU - Takahashi, Satoshi
AU  - Takahashi S
FAU - Ishige, Masayuki
AU  - Ishige M
FAU - Ishii, Yumiko
AU  - Ishii Y
FAU - Ooi, Jun
AU  - Ooi J
FAU - Tomonari, Akira
AU  - Tomonari A
FAU - Tsukada, Nobuhiro
AU  - Tsukada N
FAU - Konuma, Takaaki
AU  - Konuma T
FAU - Kato, Seiko
AU  - Kato S
FAU - Sato, Aki
AU  - Sato A
FAU - Tojo, Arinobu
AU  - Tojo A
FAU - Nakauchi, Hiromitsu
AU  - Nakauchi H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Biol Blood Marrow Transplant
JT  - Biology of blood and marrow transplantation : journal of the American Society for 
      Blood and Marrow Transplantation
JID - 9600628
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Adult
MH  - Antibodies, Monoclonal
MH  - Biomarkers, Tumor/analysis
MH  - Blood Cell Count/instrumentation/methods
MH  - Cell Differentiation
MH  - Cell Lineage
MH  - Cell Separation/instrumentation/*methods
MH  - *Cord Blood Stem Cell Transplantation
MH  - Flow Cytometry/instrumentation/*methods
MH  - Graft Rejection/*blood
MH  - Graft Survival
MH  - HLA Antigens/analysis
MH  - Hematopoietic Stem Cells/*cytology
MH  - Histocompatibility
MH  - Humans
MH  - Leukemia/*blood/diagnosis/pathology/surgery
MH  - Lymphocyte Subsets/cytology
MH  - Male
MH  - Middle Aged
MH  - Monocytes/cytology
MH  - Neoplastic Stem Cells/*cytology
MH  - Phenotype
MH  - Recurrence
EDAT- 2008/05/21 09:00
MHDA- 2008/08/20 09:00
CRDT- 2008/05/21 09:00
PHST- 2008/02/20 00:00 [received]
PHST- 2008/04/07 00:00 [accepted]
PHST- 2008/05/21 09:00 [pubmed]
PHST- 2008/08/20 09:00 [medline]
PHST- 2008/05/21 09:00 [entrez]
AID - S1083-8791(08)00145-6 [pii]
AID - 10.1016/j.bbmt.2008.04.001 [doi]
PST - ppublish
SO  - Biol Blood Marrow Transplant. 2008 Jun;14(6):693-701. doi: 
      10.1016/j.bbmt.2008.04.001.